FeesSafety
Pluang+

Quantum eMotion appoints Bernard Crotty as new independent director to boost cybersecurity growth.

Company Fundamentals
30 Sep 2026
Newsfile Corp
View Source
Bullish
Quantum eMotion appoints Bernard Crotty as new independent director to boost cybersecurity growth.

Quantum eMotion Corp. has appointed Bernard Crotty, former CEO of Certicom Corp., as an independent director on its board effective September 30, 2026. Crotty brings extensive experience in cryptography, security technology, and governance, which aligns with Quantum eMotion's focus on quantum-secure cybersecurity products. The company granted him stock options as part of his compensation. This move supports Quantum eMotion's strategy to expand its cybersecurity offerings and strengthen corporate governance as it targets commercial and government markets.

Quantum eMotion's board appointment news comes as 91 of 150 Technology-sector US stocks on Pluang fell today. For readers following Technology stocks, here is Pluang's market snapshot as of Sep 30, 2026 18:14 WIB: DOCN traded at USD 133.19 with a 1-day change of -1.35% and 84% buy order activity; SAP was priced at USD 208.19, down 1.26% with 68% sell orders; VNET rose 1.23% to USD 5.78, with 68% buy orders and a typical hold time of 15 days.

More News

Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital has closed its fifth Collateralized Loan Obligation (CLO) offering, raising $403.6 million. This deal brings the firm's total CLO issuance to more than $2 billion across five deals in less than two years, demonstrating strong investor co...

Company Fundamentals
Bullish
1 hour ago
Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

ImPact Biotech reported positive early results from its Phase 1 trial of Padeliporfin VTP in patients with locally advanced, unresectable pancreatic cancer. Of 12 patients treated, 75% have undergone or are scheduled for surgery, with over half achie...

Company Fundamentals
Bullish
1 hour ago
Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta Therapeutics presented positive preclinical and early clinical data for AVA6103, a novel peptide-drug conjugate targeting FAP-positive tumors resistant to Enhertu. AVA6103 demonstrated superior tumor control and prolonged drug release in precl...

Market News
Bullish
1 hour ago
eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware Associates has introduced a free five-minute AI readiness assessment to help regulated organizations identify and prioritize security risks related to sensitive file access in Microsoft 365 before deploying Copilot. The assessment highlight...

Others
Neutral
2 hours ago
Balchem posts Q3 2026 sales of $290.7M, net earnings up 16%, driven by growth in all segments.

Balchem posts Q3 2026 sales of $290.7M, net earnings up 16%, driven by growth in all segments.

Balchem Corporation reported strong Q3 2026 results with net sales of $290.7 million, up 8.6% year-over-year, and net earnings of $46.7 million, a 16% increase. Growth was driven by all three segments: Human Nutrition and Health, Animal Nutrition and...

Company Fundamentals
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App